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The immune responses of inbred strains of mice to certain synthetic polypeptide 
antigens are controlled by dominant immune response  (It) I genes which are closely 
linked to genes controlling expression of the major histocompatibility antigens (1, 2). 
The antibody response in mice to one  of these antigens, the random terpolymer of 
L-glutamic acid6°-I,-alaninea°-L-tyrosine  1°  (GAT), is  an  "all-or-none" response  (3,  4). 
After injection of GAT in Maal0x-pertussis anti-GAT antibody is produced by mice 
with the 11-2 genotypes a, b, d, or k  (responder strains), whereas no detectable anti- 
body to GAT is produced by mice with 11-2 genotypes p, q, or s (nonresponde'r strains). 
However,  both  responder  and  nonresponder  strains  produce  anti-GAT  antibodies 
after  immunization  with  GAT  complexed  to  methylated  bovine  serum  albumin 
(GAT-MBSA) (5, 6). 
We have used the Mishell-Dutton culture system  (7,  8)  to characterize the 
primary  and  secondary  plaque-forming  cell  (PFC)  responses  developed  by 
mouse spleen cells from both responder and nonresponder strains after stimula- 
tion  with  GAT or  GAT-MBSA in  vitro.  In  this  communication,  we will de- 
scribe the  critical parameters for stimulation of  GAT-specific PFC  responses 
in vitro and some of the characteristics of these responses. In subsequent com- 
munications, we will describe investigations of the precise nature of the cellu- 
lar functions regulated by Ir genes. 
* This investigation was supported by U.S. Public Health Service Research Grants AI- 
09897 and AI-09929 from the National Institute of Allergy  and Infectious Diseases. 
Recipient of U.S. Public Health Service Research  Career Development Award 1K4-AI- 
70173 from the National Institute of Allergy  and Infectious Diseases. 
1  Abbreviations used in this paper: C, complement;  GAT, random terpolymer of L-glutamic 
acid6°-e-alanine3°-L-tyrosinel°;  GAT-MBSA,  GAT complexed  to methylated bovine  serum 
albumin; GAT-SRBC, GAT coupled  to sheep red blood cells; HBSS, Hanks' balanced salt 
solution lacking sodium  bicarbonate; Ig,  immunoglobulin,  IgG is used  to refer  to IgG1, 
IgG2a+2b Ig in aggregate; Ir gene, immune response gene; MEM, completely supplemented 
Eagle's minimal essential medium;  PBS,  phosphate-buffered  saline; PFC,  plaque-forming 
cell(s); SRBC, sheep red blood cells. 
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Materials and Methods 
Mice.--C57B1/6J  (H-2b), SJL/J (H-2~), A/J  (H-2  a)  mice were purchased from Jackson 
Laboratories, Bar Harbor, Me. The F1 hybrid mice of (C57B1/6 X  SJL) matings (H-2  b/8) were 
produced in our animal facilities.  A.SW (H-2*) mice were purchased from Dr. G. Haughton, 
University of North Carolina; B10.S  mice were a  gift from Dr.  D.  Shreffier,  University of 
Michigan. Mice used in these studies were from 2-8-mo old and were maintained on acidified- 
chlorinated drinking water and laboratory chow ad lib. 
Antigens.---One  preparation of the random terpolymer of L-glutamic acid6°-L-alaninea°-L- 
tyrosine  1°  (GAT)  with an  average molecular weight of  55,000  was purchased from Pilot 
Chemicals Div., New England Nuclear Corporation, Boston, Mass. A second preparation of 
GAT, average molecular weight of 32,000, was purchased from Miles Laboratory, Kankakee, 
Ill. The two GAT preparations were identical in their immunological properties. Stock solu- 
tions of 10 mg/ml were prepared in normal saline containing 1% Na2COa at pH 9.0-9.5. The 
stock solution of GAT was sterilized by filtration and diluted in Hanks' balanced salt solution 
(HBSS)  for addition to spleen cell cultures. A sterile solution of GAT was complexed to a 
sterile solution of methylated bovine serum albumin (a gift from Dr. Paul Maurer, Jefferson 
Medical College) according to his technique (6). Sheep red blood cells (SRBC) were prepared 
as previously described (8) for addition to spleen cell cultures or for use in the hemolytic plaque 
assay. 
Mouse Anti-GA T Serum.--Sera were obtained from several mice undergoing a secondary 
response to GAT, pooled, decomplemented by heat at 56°C for 30  min and absorbed three 
times in the cold with packed SRBC equivalent to 20% of the volume of serum. 
Rabbit Anti-GA T Serum.--This serum, kindly donated by Dr. E. Dunham, was obtained 
from rabbits 7 days after the second immunization with 1 mg GAT in Freund's complete ad- 
juvant. The anti-GAT activity of this serum was determined by a modified Farr assay (3) and 
bound 75 #g  GAT/ml of serum. This serum was also heat inactivated and absgrbed three 
times in the cold with packed SRBC equal to 20% of the serum volume. 
Goat Antimouse  #-Chain  Serum.--This serum was a  gift from Dr.  R.  Asofsky, National 
Institutes of Health. The specificity of the serum and its effects on the development of im- 
munoglobulin (Ig)  class-specific  anfi-SRBC responses in vitro have been described in detail 
previously (9). This serum was added to spleen cell cultures with antigen at culture initiation 
as 50 #1 of a 1 : 25 dilution of serum. 
Rabbit Antimouse  Immunogloblulin Sera.--A polyvalent rabbit antimouse IgG s~rum  was 
routinely used to develop indirect PFC. Rabbit antisera specific for mouse "Y1, ")'2a+b,  or "YA 
Ig classes were used in some experiments to develop class-specific indirect PFC. The specificity 
of these sera has been previously described in detail (8). These sera were also a gift from Dr. R. 
Asofsky. 
Immunization  of Mice.--Mice were immunized with 10 #g GAT or with GAT-MBSA c~n- 
taining  10  /zg  GAT  as  a  suspension in  a  mixture of magnesium-aluminum hydroxide gel 
(Maalox, Wm. H. Rorer, Inc., Fort Washington, Pa.) and pertussis vaccine (Eli Lilly and Co., 
Indianapolis, Ind.) as previously described (3). 
Preparation  of GAT  Coupled SRBC (GAT-SRBC).--GAT  was  coupled  to  SRBC  with 
chromium chloride (CrC13) (J. T. Baker Chemical Co., Phillipsburg, N. J.) by a modification 
of the method described by Gold and Fudenberg (10). The optimal ratio of reactants was de- 
termined empirically and is described below. SRBC in Alsever's  solution (Colorado Serum Co., 
Denver, Cvl.)  were washed three times by centrifugation and resuspended to 10~ in 0.85% 
NaC1. CrCla was pulverized and dissolved in 0.85% NaC1 (10 mg/ml) immediately before use. 
At room temperaure, 1.0 ml of 10%  SRBC was mixed with 1.0 ml of the GAT solution (10 
mg/ml) in a 50 ml centrifuge tube. 1 ml of the freshly prepared solution of CrCls was pipetted 
into the mixture of GAT and SRBC. The reaction was allowed to proceed for 1-2 min without 
stirring and was terminated by adding 45 ml of PBS (0.15M  NaC] containing 0.001 M phos- j. A. KAPP,  C. W. PIERCE,  AND  B. BENACERRAF  1109 
phates, pH 7.2). The coupled cells were washed three times by centrifugation with 50 ml PBS 
and resuspended in medium L-15 (Microbiological Associates, Bethesda, Md.) to 1% for the 
51Cr release assay or to 7.5% for the hemolytic plaque assay. 
Antibody-Me.dialed  Lysis of GA T-SRBC.--The  susceptibility of GAT-SRBC indicator cells 
to lysis by anti-GAT antibodies and complement (C) was determined. SRBC and GAT-SRBC 
were labeled with SlCr by reacting 0.1 mCi Na251CrO4 (The  Radiochemical Centre, Amer- 
sham, England) with 3 X  108 cells in 1.0 ml of medium L-IS for 30 min at 37°C. The cells were 
washed three times by centrifugation with 50 ml volumes of L-15  containing 10% fetal calf 
serum. The 51Cr-labeled cells, 0.1 ml of 3 X  l0  T  cell/ml, were mixed with 0.1 ml of diluted mouse 
anti-GAT serum and 0.1 ml of guinea pig serum (BBL Div. of BioQuest, Cockeysville, Md.) 
as a source of C. After incubation at 37°C for 1 h, the amount of 51Cr released into the super- 
nate was determined using a Packard gamma scintillation counter (Packard Instrument Co., 
Inc., Downers Grove, Ill.). The percent of 51Cr released by the antiserum was determined using 
a distilled water-lysed control as 100% release and subtracting the amount of 51Cr released by 
C alone from the total released by antiserum and C by the following relationship: 
(S1Cr released by antiserum -b C)  --  (SXCr released by C) 
%S1Cr release  =  (siC  r released by H20 lysis)  --  (SaCr released by C)  X  100. 
Reproducibility  of Coupling GA T to SRBC.--GAT-SRBC prepared on several different days 
with GAT were tested with one mouse anti-GAT serum and C in the 51Cr release assay. Com- 
parison of the 50% end points in Fig. 1, shows a difference of less than one twofold dilution in- 
dicating that this method of preparation GAT-SRBC provided indicatgr ceils which measure 
anti-GAT activityin serum in a consistent  manner. This anti-GAT serum released no 5XCr  when 
tested on uncoupled SRBC. When GAT-SRBC prepared with GAT from Miles Laboratory or 
from Pilot Chemicals Co. were compared in a 51Cr release assay there was no significant differ- 
ence in 50% end points with the standard mouse anti-GAT serum. Furthermore, when soluble 
GAT was added to a  1~0 dilution of this serum, 100% of the 51Cr released by the anti-GAT 
serum was inhibited with GAT at concentrations of 0.1/zg or greater. These concentrations of 
GAT had no effect on the release of 51Cr from labeled SRBC by an anti-SRBC serum. GAT- 
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FIG. 1.  Percent of SlCr released specifically  from 51Cr-labeled GAT-SRBC by a standard 
mouse anti-GAT serum and complement. Each line represents a separate experiment with a 
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SRBC indicator cells prepared by this method can also be used in microtiter systems to detect 
hemagglutinating activity in sera of mice immunized with GAT or GAT-MBSA in vivo. 
Spleen Cell Cultures.--Suspensions of single spleen cells containing 10 X  10 6 nucleated cells/ 
ml of culture medium (MEM) were incubated according t? the method of Mishell and Dutton 
(7) with modifications previously described in detail (8). Experimental groups were incubated 
as duplicate cultures and each experiment contained cultures unstimulated, stimulated with 
10 7 SRBC, and appropriate concentrations of GAT or GAT-MBSA. 
Hemolytic Plaque  Assay.--PFC in spleen cell cultures or in the spleens of mice immunized 
in vivo were enumerated by a modification of the Jerne hemolytic plaque technique described 
in detail previously (8). Suspensions of spleen ceils were washed three times before assay to re- 
move any soluble GAT. IgM PFC were enumerated after incubation of indicator red  cells, 
SRBC or GAT-SRBC, and spleen cells in semi-solid  agarose using guinea pig serum as a source 
of C. IgG PFC were developed with polyvalent rabbit antimouse IgG serum and C in assay 
preparations containing sufficient goat antimouse #-chain antibody to inhibit the development 
of all IgM PFC (8). Each cell suspension was examined in agarose mixtures c~ntaining SRBC 
and in mixtures containing GAT-SRBC.  The specificity of anti-GAT  PFC  was verified  by 
adding 10 #g of soluble GAT to the assay mix tures to inhbit development of anti-GAT plaques. 
This concentration of soluble GAT reproducibly inhibited all anti-GAT PFC, while causing no, 
nonspecific, inhibition of development of anti-SRBC PFC. GAT-specific PFC were calculated 
by subtracting the number of PFC uninhibited by soluble GAT on GAT-SRBC from the num- 
ber of PFC detected on GAT-SRBC in the absence of soluble GAT. Data are expressed as GAT- 
specific PFC/spleen for in vivo experiments and as GAT-specific  PFC/culture for in vitro ex- 
periments. 
RESULTS 
Primary  GAT-Specific  Responses In  Vivo.--In  preliminary  experiments, 
the first GAT-specific  PFC in  C57B1/6  mice were detected 4 days after im- 
munization  with  GAT  and  the  maximum  number  was  obtained  by day  7. 
Fig.  2 illustrates  the primary GAT-specific  PFC responses  in spleens  of SJL 
(nonresponders),  C57B1/6 (responders),  and  the F: hybrid of C57B1/6  X  SJL 
(responders)  mice 7 days after immunization  in vivo with  10/~g  of GAT as 
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FIG. 2.  Primary IgO OAT-specific  PFC responses in spleens from C57B1/6, SJL/J, and 
F: (C57 X  SJL) mice immunized intraperitoneally 7 days before assay" with 10/~g  OAT as 
GAT-MB SA in Maalox-per  tussls. ]. A. KAPP, C. W. PIERCE, AND  B. BENACERRAF  1111 
GAT-MBSA in Maalox-pertussis. No IgM PFC specific for GAT were found 
in the spleens of any of these mice at any time from 4 to 15 days after immuni- 
zation. The C57B1/6 and  the F1 mice developed GAT-specific  IgG PFC re- 
sponses when immunized with GAT, whereas  the SJL mice did not. All three 
strains developed GAT-specific IgG PFC responses  to GAT-MBSA. 
Development of _Primary and  Secondary GAT-Specific  PFC Responses In 
Vitro.--Spleen  cells from normal C57B1/6,  SJL, and the F1 (C57B1/6 X  SJL) 
mice were stimulated in vitro with either 107 SRBC, GAT-MBSA (5/zg GAT/ 
culture), or various concentrations of soluble  GAT. After 5 days, the time of 
the maximum response  to SRBC, the cultures were examined for anti-SRBC 
PFC and anti-GAT PFC. The results in Fig. 3 show that cultures of C57B1/6 
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Fro. 3.  Primary IgG GAT-specific PFC responses in cultures of spleen cells from C57B1/6, 
SJL, and F1 (C57 X  SJL) mice stimulated with various doses of soluble GAT in vitro. The bar 
graph shows the IgG GAT-specific PFC responses in cultures of the same preparations of spleen 
cells stimulated with 5.0 #g CAT as GAT-MBSA. 
and  F1  spleen  cells  developed  GAT-specific  IgG  PFC  responses  to  several 
doses of soluble GAT. Although 10 ~g GAT stimulated the maximum response 
in cultures of C57B1/6 spleen cells in this experiment, many other experiments 
have shown that 1 #g and 10 #g GAT stimulated comparable PFC responses; 
concentrations of soluble GAT higher than 10 #g always elicited a lower PFC 
response.  Cultures of SJL spleen cells developed no GAT-specific IgG response 
at any concentration of GAT. All three strains developed GAT-specific  IgG 
PFC  responses  to  GAT-MBSA,  and,  although not shown,  all  three  strains 
developed IgM and IgG anti-SRBC PFC responses. Again,  no IgM PFC spe- 
cific for GAT were detected in any of these cultures. 
Kinetics of Appearance of GAT-Specific IgG PFC.--Cultures of spleen cells 
from  normal  C57B1/6  and  SJL mice,  and  C57B1/6  mice  immunized  6 wk 
earlier with  10/~g  GAT in Maalox-pertussis were examined at various times 
after initiation for the  development of PFC  responses  to SRBC  and  GAT. 1112  GENETIC  CONTROL  OF  IMMUNE  RESPONSES  IN  VITRO 
At the time this experiment was done, 1 #g GAT elicited the maximal GAT- 
specific PFC responses in cultures of spleen cells from normal  C57B1/6 mice. 
The GAT-specific IgG PFC response in cultures of C57B1/6 spleen cells (Fig. 
4) reached a peak after 5 days incubation with 1/~g of GAT; no GAT-specific 
IgG PFC response was detected in cultures incubated with 0.1/~g GAT. Spleen 
cells from C57B1/6 mice primed with GAT developed GAT-specific IgG PFC 
responses to both 0.1  ]~g and  1.0/~g GAT (Fig. 5), which also reached peaks 
after 5 days incubation. The GAT-specific PFC responses by spleen cells from 
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FIG. 4. Kinetics  of  the  primary  IgG PFC responses  in  cultures  of spleen  cells  from C57BI/6 
mice stimulated with 10  v SRBC, 1.0 ~g GAT, or 0.1/zg GAT. 
GAT-primed mice were always approximately two times greater in magnitude 
than the responses in cultures of spleen cells  from normal  C57B1/6 mice. No 
IgM PFC specific for GAT were detected at any time in cultures of normal or 
primed  spleen cells  from C57B1/6 mice. Spleen cells from normal  SJL mice 
(Fig.  6)  did not develop GAT-specific IgM  or IgG PFC  responses to either 
dose of soluble GAT at any time, however, they did develop an anti-SRBC 
IgM  and  IgG  PFC  response reaching a  peak  after 4  days incubation  with 
SRBC. In subsequent in vitro studies,  the PFC responses were assayed after 
5 days incubation. J.  A.  KAPP~ C.  W.  PIERCE~  AND  B.  BENACERRAF  1113 
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Fro. 5.  Kineticsof  thesecondaryIgGPFC  responses  in cultures of spleen cells frome57Bl/6 
mice immunized with 10 #g GAT in Maalox-pertussis 4 wk before culture initiation and stimu- 
lated in vitro with l0 T  SRBC, 1.0/~g GAT, or 0.1 #g GAT. 
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TIC.  6.  Kinetics of the primary IgG PFC responses in cultures of spleen cells from SJL mice 
stimulated with l0 T  SRBC, 1.0 #g GAT, or 0.1 ~g OAT. 1114  GENETIC  CONTROL  OF  IMMUNE  RESPONSES  IN  VITRO 
Specificity  of Stimulation  by  GAT  In  Vitro.--The  experiment  shown  in 
Fig.  7 demonstrates that the primary GAT-specific PFC response in  cultures 
of C57B1/6 spleen cells was the result of specific antigenic stimulation by GAT. 
Rabbit anti-GAT  serum,  extensively absorbed with  SRBC  in  the  cold,  was 
added  to cultures stimulated with SRBC  or GAT at culture  initiation.  50 pl 
of a 1~25  dilution of this serum had no effect on the anti SRBC IgG PFC re- 
sponse, but,  completely inhibited  the GAT-specific IgG PFC response stimu- 
lated by 10/~g GAT. 50 #i of a 1/625 dilution of anti-GAT serum had no effect 
on either the anti-SRBC or GAT-specific PFC responses. 
Immunoglobulin Class of GA T-Specific  PFC.--The Ig class of the antibody 
synthesized by GAT-specific PFC was examined by developing the PFC with 
class-specific rabbit  antimouse ~'1, ~/2a+b, and "YA sera.  For  reference,  the  Ig 
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FIO. 7.  The effect of rabbit anti-GAT serum on the IgG PFC responses  in cultures of spleen 
cells from C57B1/6 mice stimulated with l0 T  SRBC or 10 #g GAT. 50 #1 of a 1/125 or 1/625 di- 
lution of the antiserum was added at culture initiation. 
classes of anti-SRBC PFC were also determined. The results in Table I  show 
that anti-SRBC  PFC in cultures of spleen cells from C57B1/6 and SJL mice 
are approximately 50% 71,30% ")'2, and 12-20% ")'A • The GAT-specific PFC 
in cultures of spleen cells from normal SJL mice stimulated in vitro with GAT- 
MBSA,  and  from  normal  C57B1/6  mice  stimulated  in vitro  with  GAT  or 
GAT-MBSA were 80-100% "Yl, 0-3 % ")'2, and 6-18 % "YA • Whereas, primary 
GAT-specific PFC responses by C57B1/6  and SJL spleen cells were predomi- 
nately of the "y~ class, with few or no "g~ PFC,  the secondary GAT-specific re- 
sponses by SJL spleen cells stimulated with GAT-MBSA and C57B1/6 spleen 
cells stimulated with GAT contained significant numbers of GAT-specific PFC 
of the ~  Ig class. The total number of PFC  developed by the class-specific 
antisera does not equal the number of PFC developed by the polyvalent rabbit 
anti-IgG serum, nor is it expected to, since the polyvalent serum is not a pool 
of the class-specific sera. J. A.  I~APP,  C. W.  PIERCE,  AND  B.  BENACERRAF  1115 
TABLE I 
Immunoglobulin Class ~ GAT-Spec~cPFC 
Mouse  Antigen  Indicator cells  strain 
PFC/culture 
IgG*  IgGl  IgG~s+~b  IgA 
C57B1/6:~  SRBC  SRBC  4,200  2,635  1,480  590 
GAT  GAT-SRBC  1,375  1,155  25  80 
GAT  GAT-SRBC  880  160  5  20 
GAT-MBSA  GAT-SRBC  300  90  0  20 
C57B1/6§  GAT  GAT-SRBC  745  370  160  120 
SJL/J~  SRBC  SRBC  1,740  2,060  1,020  585 
GAT-MBSA  GAT-SRBC  575  365  0  0 
SJL/JI[  GAT-MBSA  GAT-SRBC  450  285  40  25 
* These PFC were developed  with a polyvalent rabbit antimouse IgG serum. 
Normal spleen cells. 
§ Spleen cells  from mice primed with 10 #g GAT in Maalox-pertussis 6 wk previously. 
[I Spleen cells from mice primed with 10/zg GAT as GAT-MBSA in Maalox-pertussis 6 wk 
previously. 
Effect of Antimouse #-Chain Serum on the Development  o/GAT-Specific  PFC 
Responses In  Vitro.--We have never detected IgM PFC  specific for GAT  in 
these experiments. This is unusual  since IgM antibodies are usually  found in 
responses to antigens which also stimulate synthesis of IgG antibodies. Further- 
more, as previously reported,  both primary IgM and IgG PFC  responses to 
SRBC  in vitro can be inhibited  by incubating spleen cells in the  presence of 
goat antibody to mouse/z-chain. This suppression by anti-/z-chain serum  was 
shown to be mediated through the precursors of antibody-producing  cells pre- 
sumably by combining with the IgM surface receptors for antigen  and thus 
preventing effective stimulation by. antigen  (9). If the GAT-specific IgG PFC 
response by spleen cells in vitro could also be inhibited with anti-/~-chain serum, 
this would be presumptive evidence that precursors of GAT-specific PFC had 
IgM receptors for antigen on their cell surface. 50 #1 of a 1/65 or 1/~0  0 dilution  of 
goat anti-/z-chain serum was added to cultures of C57B1/6  spleen cells stimu- 
lated with  SRBC,  GAT, or  GAT-MBSA and to cultures  of SJL spleen  cells 
stimulated  with  SRBC  and  GAT-MBSA  at  culture  initiation.  The  results 
(Table II) demonstrate that GAT-specific IgG PFC responses in both strains 
were inhibited 90 % or more by incubation with the 1/~5 dilution of anti-/z-chain 
serum; the 1~0 0 dilution suppressed the responses by 60-100%. 
Responses of Various Strains of Mice to GA T and GA T-MBSA In Vitro.--To 
rule out any possibility that the failure of spleen cells from SJL mice to respond 
to soluble GAT in vitro is a peculiarity of this particular strain of mice rather 
than being attributable to the H-2  ~ genotype, we tested two congenic It-28 non- 
responder strains of mice in our system. We chose the B10.S strain, a congenic 
resistant strain of the H-28 histocompatibility genotype on a  C57B1/10 back- 1116  GENETIC  CONTROL  OF IMMUNE  RESPONSES  IN  VITRO 
TABLE II 
Effect of Anti Mouse #-Chain  Serum  on Development  of Primary PFC Responses In  Vitro 
Mouse  Dilution of  Antigen  Indicator ceils 
strain  antiserum* 
PFC/culture 
IgM  IgG 
C57B1/6  None  SRBC  SRBC  750  2,135 
1/25  SRBC  SRBC  5  140 
1/100  SRBC  SRBC  180  475 
None  GAT  GAT-SRBC  0  410 
1/25  GAT  GAT-SRBC  0  5 
1/100  GAT  GAT-SRBC  0  75 
None  GAT-MBSA  GAT-SRBC  0  300 
1/25  GAT-MBSA  GAT-SRBC  0  0 
1/100  GAT-MBSA  GAT-SRBC  0  125 
SJL  None  SRBC  SRBC  1,920  1, ll0 
1/25  SRBC  SRBC  0  60 
1/100  SRBC  SRBC  95  135 
None  GAT-MBSA  GAT-SRBC  0  245 
1/25  GAT-MBSA  GAT-SRBC  0  0 
1  / 100  GAT-MB  SA  GAT-SRB  C  0  0 
* Anti-/z serum was added to 1.0 ml cultures as 50/zl of the indicated dilution. 
ground. This strain has the same H-2 type as the SJL, and is otherwise essen- 
tially identical with the C57B1/6 responder mice used in these studies.  We also 
tested  the A.SW strain  of mice,  a  congenic resistant  strain  also of the  H-2  ~ 
histocompatibility type, but  on an A  strain  background. A/J mice were in- 
cluded in this study since they possess the same non-H-2 genotype as the A.SW, 
but they have the H-2  ~ histocompatibility type and are thus responders to GAT. 
Spleen cells from all five strains were incubated with SRBC, or 10/zg GAT, or 
5/zg GAT as GAT-MBSA. All strains developed IgM and IgG anti-SRBC PFC 
responses. The GAT-specific IgG PFC responses to GAT and GAT-MBSA are 
shown in Fig. 8.  No IgM PFC specific  for GAT were detected in cultures of 
any of these mice.  Spleen cells  from all five strains  of mice developed GAT- 
specific IgG PFC responses to  GAT-MBSA; but only the  C57B1/6 and A/J 
strains developed responses to soluble GAT. None of the three strains of mice 
bearing the  H-28  genotype developed a  response  to  soluble  GAT in  culture, 
proving that this failure is not a peculiarity of the SJL strain of mice. Further- 
more, the linkage of responsiveness to GAT and t/-2 histocompatibility type 
previously  reported  using  in  vivo  serological  techniques  (3)  has  now  been 
demonstrated for PFC responses using an in vitro system. 
DISCUSSION 
These  experiments  demonstrate  that  mouse  antibody  to  the  random  ter- 
polymer GAT can be detected by complement-dependent lysis of SRBC which 
have GAT complexed to their surfaces. This hemolysis can be quantitated by j.  A.  KAPP,  C.  W.  PIERCE,  AND  B.  BENACERRAF  1117 
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FIG. 8.  Comparison of the IgG GAT-specific PFC responses in cultures of spleen ceils from 
responder and nonresponder strains of mice stimulated with 10 #g GAT or 5 #g GAT as GAT- 
MBSA. 
measuring the percent of 51Cr released from 5~Cr-labeled GAT-SRBC by serum 
antibodies or by enumerating localized areas of hemolysis formed by antibodies 
released from lymphoid cells in a hemolytic plaque assay using GAT-SRBC as 
the indicator cells. Using GAT-SRBC as indicator cells in the hemolytic plaque 
assay, we have shown that primary and secondary PFC responses specific for 
GAT can be stimulated in cultures of spleen cells from responder mice incubated 
with  soluble GAT or with  the particulate GAT-MBSA. Furthermore,  GAT- 
specific PFC  can be stimulated in cultures of spleen cells from nonresponder 
mice incubated with GAT-MBSA, but not in cultures incubated with GAT. 
The maximal GAT-specific PFC responses were detected 5 days after culture initia- 
tion; the  optimal concentration of soluble GAT varied between  1 to  10 #g  GAT/ 
culture. In the primary response in vitro, all detected GAT-specific PFC elicited by 
GAT or GAT-MBSA have been indirect PFC predominantly of the 71 class with few 
or no PFC of the 7~ class. The majority of GAT-specific PFC in the secondary re- 
sponse  in vitro are also of  the 71  class, but  a  significant number  of  GAT-specific 
PFC  of 73  class are also detected. No  direct, IgM,  GAT-specific PFC  have  been 
detected in vivo or in vitro. There are three possible explanations for this observa- 
tion: (a) IgM antibodies specific for GAT are produced but GAT-SRBC are not lysed 
by these antibodies in the presence of complement; (b) some IgM GAT-specific PFC 
are present but are too few in number or too transient in their secretory phase to be 
detected; or (c) no IgM antibodies to GAT are synthesized. There is no direct evi- 
dence  to  support  any  one  of these possibilities; however,  some circumstantial evi- 
dence  suggests  that  the first explanation is unlikely. That  is, we have found  that 
equal numbers of IgM anti-SRBC PFC can be detected using SRBC or GAT-SRBC 
as indicator cells. Therefore, the coupling of GAT to the SRBC has not rendered the 
red cells insensitive to lysis by IgM antibody and complement. Unless mouse IgM 
anti-GAT antibody is unable to fix complement, the first explanation is an unlikely 1118  GENETIC  CONTROL  OF  IMMUNE  RESPONSES  IN  VITRO 
possibility. Although  the  finding  that  development of  GAT-specific  IgG PFC  re- 
sponses can be inhibited by incubation of the spleen cell cultures with goat antimouse 
t~-chain serum tells us that anti-GAT PFC precursors have IgM receptors for antigen 
on their cell surfaces,  it does not tell  us whether or not IgM antibodies specific for 
GAT are ever synthesized.  At this time, we cannot choose between explanations 2 and 
3.  The lack of detectable IgM antibody specific for GAT is nonetheless  significant. 
GAT elicits an all-or-none  response  in  mice and  thus  differs  from some  other syn- 
thetic polypeptide antigens the response  to which is under the control of Ir genes. (T, 
G)-A-L, for example,  elicits an IgM antibody response  in all strains of mice, but an 
IgG response only in  those strains possessing  the  appropriate Ir gene  (11, 12). If 
little  or no IgM anti-GAT antibody is synthesized  in  mice after stimulation with 
GAT, then the all-or-none  character of this immune response is the same as the all-or- 
none character of the IgG response  to (T, G)-A-L. 
The GAT-specific IgG PFC response in cultures of spleen cells from various 
inbred strains of mice stimulated  with  GAT or GAT-MBSA in vitro was in- 
vestigated.  Cultures  of spleen  cells from mice of the H-2 ~ histocompatibility 
type (S  J-L, B10.S, A.SW), which were previously classified by serological tech- 
niques  as  nonresponder  strains  (3),  produced  no  GAT-specific  PFC  when 
incubated with GAT in vitro. Cultures of spleen cells from C57B1/6 (11-2  b) and 
A/J (H-2  ~) mice, previously classifed as responder strains, produced IgG PFC 
specific for  GAT when  stimulated  with  soluble  GAT in  vitro.  GAT-specific 
IgG PFC responses developed in cultures of spleen cells from both responder 
and  nonresponder  strains  which  were stimulated  with  GAT-MBSA in vitro. 
The  development of  GAT-specific PFC  responses  in  cultures  of spleen  cells 
from H-2" nonresponder mice stimulated with GAT-MBSA demonstrates that 
nonresponder mice have precursors of antibody-producing cells specific for GAT 
and  that  those cells have the capacity to synthesize GAT-specific antibodies 
when  stimulated  under  the  appropriate circumstances.  The failure of spleen 
cell cultures  of nonresponder mice to synthesize antibodies specific for GAT 
when stimulated with soluble GAT suggests that these mice lack GAT-specific 
thymus-derived "helper" cells. 
The  immune  response genes  controlling  the  response  to  GAT were  again 
demonstrated to be linked to the genes controlling the H-2 antigens. The domi- 
nance  of this  Ir gene  is shown  by the  ability of the  F1  (C57  X  SJL)  mice 
(11-2  b/~) to develop GAT-specific PFC responses when stimulated with soluble 
GAT in vitro. 
These data therefore show that genetic control of GAT-specific PFC responses 
in vitro correlates precisely with previous data obtained by measuring serum 
antibody responses to GAT. The in vitro system described in this study will be 
used  as a  model to study the  cellular events regulated by the H-2-1inked Ir 
genes. The cellular requirements for the development of antibody responses to 
GAT and GAT-MBSA in vitro are the subject of the accompanying paper (13). 
Subsequent  papers in  this  series will  deal with  the  cellular defect(s)  in non- j.  A.  KAPP, C.  W.  PIERCE~ AND B.  BENACERRAF  1119 
responder  mice  which  are  responsible  for  their  failure  to  develop  antibody 
responses to soluble GAT both in vivo and in vitro. 
SUMMARY 
In vivo, the antibody response in mice to the random terpolymer L-glutamic 
acid6°-L-alanine3°-L-tyrosine  1°  (GAT)  is  controlled  by  a  histocompatibility- 
linked immune response gene(s). We have studied antibody responses by spleen 
cells from responder and nonresponder mice to GAT and GAT complexed to 
methylated  bovine  serum  albumin  (GAT-MBSA)  in  vitro.  Cells  producing 
antibodies specific for GAT were enumerated in a modified Jerne plaque assay 
using GAT coupled to sheep erythrocytes as indicator cells. Soluble GAT stimu- 
lated development of IgG GAT-specific plaque-forming cell  (PFC)  responses 
in cultures of spleen cells from responder mice, C57B1/6 (H-2b), F1 (C57)<  SJL) 
(H-2b/8), and A/J (H-2a). Soluble GAT did not stimulate development of GAT- 
specific PFC responses in cultures of spleen cells from nonresponder mice, SJL 
(H-2*), B10.S (H-28), and A.SW (H-2"). GAT-MBSA stimulated development of 
IgG GAT-specific PFC responses in cultures of spleen cells from both responder 
and  nonresponder  strains  of mice.  These  data  correlate precisely with  data 
obtained by measuring the in vivo responses of responder  and nonresponder 
strains of mice to GAT and GAT-MBSA by serological techniques.  Therefore, 
this in vitro system can effectively be used as a  model to study the  cellular 
events regulated by histocompatibility-linked immune response genes. 
REFERENCES 
1.  Benacerraf,  B.,  and H.  O.  McDevitt.  1972. Histocompatibility-linked immune 
response genes. Science (Wash. D. C.). 175:273. 
2.  McDevitt, H. O., and B. Benacerrai. 1969. Genetic control of immune responses. 
Adv. Immunol. 11:31. 
3.  Martin, J. W., P. H. Maurer,  and B. Benacerraf.  1971. Genetic control of im- 
mune responsiveness  to a glutamic acid,  alanine,  tyrosine copolymer in mice. 
J. Immunol. 107:715. 
4.  Merryman, C. F., and P. H. Maurer.  1972. Genetic control of immune response 
to glutamic acid,  alanine,  tyrosine copolymers in mice.  I. Association  of re- 
sponsiveness  to  H-2  genotype  and  specificity  of  the  response.  J.  Immunol. 
108:135. 
5.  Dunham, E. K., E. R. Unanue,  and B. Benacerraf.  1972. Antigen-binding  and 
capping by lymphocytes of genetic  nonresponder mice. J. Exp. Med. 136:403. 
6.  Gershon,  R. K., P. H. Maurer, and C. F. Merryman. 1973. A cellular  basis for 
.genetically  controlled  immunologic-unresponsiveness  in  mice:  Tolerance 
induction  in T  cells. Proc. Natl.  Acad.  Sci.  U.S.A. 70:250. 
7.  Mishell,  R.  I.,  and  R.  W.  Dutton.  1967. Immunization of  dissociated  spleen 
cell cultures from normal mice. J. Exp. Med.  126:423. 
8.  Pierce, C. W., B. M. Johnson, H. E.  Gershon,  and R. Asofsky.  1971. Immune 
responses  in  vitro.  III. Development of  primary 3'M,  3'G and  3'A plaque- 1120  GENETIC  CONTROL  OF  IMMUNE  RESPONSES  IN  VITRO 
forming cell responses in mouse spleen  cell cultures stimulated  with heterolo- 
gous erythrocytes. J. Exp. Med. 134:395. 
9.  Pierce, C. W., S. M. Solliday,  and R. Asofsky. 1972. Immune responses in vitro. 
IV. Suppression of primary "},M, ~G and "yA plaque-forming cell responses in 
mouse spleen cell cultures by class-specific antibody to mouse immunoglobulins. 
J. Exp. Med. 135:675. 
10.  Gold,  E. R., and H. H. Fudenberg.  1967.  Chromic chloride: A coupling reagent 
for passive hemagglutination reactions. J. Immunol.  99:859. 
Ii.  Grumet, F. C.  1972. Genetic control of the  immune response. A selective  defect 
in immunologic (IgG) memory in nonresponder mice.  J. Exp. Med.  135:110. 
12.  Mitchell,  G.  F.,  F.  C.  Grumet,  and  H.  O.  McDevitt.  1972.  Genetic control of 
the immune response. The effect of thymectomy on the primary and secondary 
antibody  response  of  mice  to  poly-z-(Tyr,  Glu)-poly-D-Ala-poly-L-Lys. J. 
Exp. Med. 135:126. 
13.  Kapp,  J.  A.,  C.  W.  Pierce,  and  B.  Benacerraf.  Genetic  control of immune re- 
sponses  in  vitro.  II.  Cellular  requirements  of  primary  plaque-forming  cell 
responses  to the random  terpolymer L-glutamic acid6°-z-alaninea°-z-tyrosine  z° 
(GAT) by mouse spleen  cells in vitro. 138:1121. 